



Supplemental Fig. S1. Patient selection flowchart. FIB-4, fibrosis-4; LSM, liver stiffness measurement. ^aAbdominal obesity, elevated triglyceride, reduced high-density lipoprotein cholesterol, elevated blood pressure, and elevated fasting glucose (impaired fasting glucose or type 2 diabetes); ^bDiagnosed with ultrasound (increased echogenicity of the liver parenchyma relative to that of the cortex of the kidneys, unclear visualization of the intrahepatic vessels, and/or deep beam attenuation) or transient elastography (TE) (FibroScan; controlled attenuation parameter ≥ 248 dB/m). TE was performed in all participants; ^cLiver biopsy was performed if the patented serum tests (cutoffs to use: enhanced liver fibrosis 9.8; FibroMeter 0.45, Fibrotest 0.48) were discordant with LSM.